Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.

York Springer, Ajcc Cancer Staging Manual. 7th Ed. New ,(2010)

Volkmar Müller, Nicole Stahmann, Sabine Riethdorf, Thomas Rau, Tanja Zabel, Alexander Goetz, Fritz Jänicke, Klaus Pantel, Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity Clinical Cancer Research. ,vol. 11, pp. 3678- 3685 ,(2005) , 10.1158/1078-0432.CCR-04-2469

Leslie K. Diaz, Vincent L. Cryns, W. Fraser Symmans, Nour Sneige, Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Advances in Anatomic Pathology. ,vol. 14, pp. 419- 430 ,(2007) , 10.1097/PAP.0B013E3181594733

Gunter von Minckwitz, Neoadjuvant chemotherapy in breast cancer—insights from the German experience Breast Cancer. ,vol. 19, pp. 282- 288 ,(2012) , 10.1007/S12282-012-0393-7

F.-C. Bidard, C. Mathiot, S. Delaloge, E. Brain, S. Giachetti, P. de Cremoux, M. Marty, J.-Y. Pierga, Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer Annals of Oncology. ,vol. 21, pp. 729- 733 ,(2010) , 10.1093/ANNONC/MDP391

Mitra Tewes, Bahriye Aktas, Anja Welt, Siemke Mueller, Siegfried Hauch, Rainer Kimmig, Sabine Kasimir-Bauer, Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies Breast Cancer Research and Treatment. ,vol. 115, pp. 581- 590 ,(2009) , 10.1007/S10549-008-0143-X

Barbara L. Smith, Neoadjuvant versus adjuvant systemic therapy for operable breast cancer: equivalent outcomes? Annals of Surgery. ,vol. 257, pp. 180- 181 ,(2013) , 10.1097/SLA.0B013E318280A688

Pia Wülfing, Julia Borchard, Horst Buerger, Stefan Heidl, Kurt S. Zänker, Ludwig Kiesel, Burkhard Brandt, HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients Clinical Cancer Research. ,vol. 12, pp. 1715- 1720 ,(2006) , 10.1158/1078-0432.CCR-05-2087

Michail Ignatiadis, Françoise Rothé, Carole Chaboteaux, Virginie Durbecq, Ghizlane Rouas, Carmen Criscitiello, Jessica Metallo, Naima Kheddoumi, Sandeep K. Singhal, Stefan Michiels, Isabelle Veys, José Rossari, Denis Larsimont, Birgit Carly, Marta Pestrin, Silvia Bessi, Frédéric Buxant, Fabienne Liebens, Martine Piccart, Christos Sotiriou, HER2-Positive Circulating Tumor Cells in Breast Cancer PLOS ONE. ,vol. 6, ,(2011) , 10.1371/JOURNAL.PONE.0015624

Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M Swain, Tatiana Prowell, Sibylle Loibl, D Lawrence Wickerham, Jan Bogaerts, Jose Baselga, Charles Perou, Gideon Blumenthal, Jens Blohmer, Eleftherios P Mamounas, Jonas Bergh, Vladimir Semiglazov, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, Wolfgang Eiermann, Gunter Von Minckwitz, None, Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis The Lancet. ,vol. 384, pp. 164- 172 ,(2014) , 10.1016/S0140-6736(13)62422-8